SCOPUS 정보 검색 플랫폼

Volumn 360, Issue 9350, 2002, Pages 2086-2087

ICON3 and chemotherapy for ovarian cancer [14] (multiple letters)

(14) Ozols, Robert F a,b,c Markman, Maurie b,c Thigpen, J Tate b,c Earl, Helena d Pilotti, Silvana e Oggionni, Maria e Böhm, Silvia e Pierotti, Marco A e Zunino, Franco e Parmar, Mahesh f Harper, Peter f Colombo, Nicoletta f Torri, Valter f Guthrie, David f

a FOX CHASE CANCER CENTER (United States)

b LERNER RESEARCH INSTITUTE (United States)

c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE (United States)

d UNIVERSITY OF CAMBRIDGE (United Kingdom)

e NATIONAL CANCER INSTITUTE (Italy)

f MRC CLINICAL TRIALS UNIT (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; HUMAN; LETTER; MINIMAL RESIDUAL DISEASE; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0037153733 PISSN: 01406736 EISSN: None Source Type: Journal
DOI: 10.1016/s0140-6736(02)11984-2 Document Type: Letter

Times cited : (10)

References (5)

1
- 0037125582
- Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial
- The International Collaborative Ovarian Neoplasm (ICON) Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial Lancet 360 2002 505 515
- (2002) Lancet , vol.360 , pp. 505-515
- The International Collaborative Ovarian Neoplasm (ICON) Group¹

2
- 0030054309
- Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
- WP McGuire WJ Hoskins MF Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
- (1996) N Engl J Med , vol.334 , pp. 1-6
- McGuire, WP¹ Hoskins, WJ² Brady, MF³

3
- 0034600305
- Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
- MJ Piccart K Bertelsen K James Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Natl Cancer Inst 92 2000 699 708
- (2000) J Natl Cancer Inst , vol.92 , pp. 699-708
- Piccart, MJ¹ Bertelsen, K² James, K³

4
- 0000121237
- Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG158)
- RF Ozols BN Bundy J Fowler Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG158) Proc Am Soc Clin Oncol 18 1999 1373A
- (1999) Proc Am Soc Clin Oncol , vol.18 , pp. 1373A
- Ozols, RF¹ Bundy, BN² Fowler, J³

5
- 0033986363
- Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study
- FM Muggia PS Braly MF Brady Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study J Clin Oncol 18 2000 106 115
- (2000) J Clin Oncol , vol.18 , pp. 106-115
- Muggia, FM¹ Braly, PS² Brady, MF³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.